# cancer and autoimmune diseases, today FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/cancer-and-autoimmune-diseases-today

> No upcoming FDA catalysts in cancer and autoimmune diseases, today; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 29, 2025 | [Xencor Inc interim data readout](https://sec-api.dev/companies/xncr/catalysts) | XNCR | cancer and autoimmune diseases, today | completed, positive | "PASADENA, Calif. -- Apr. 29, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/xncr-20250429xexx992.htm)) |
| May 29, 2025 | [ARTEMIS (artemis) trial start](https://sec-api.dev/pdufa/artemis) | ESLA | cancer and autoimmune diseases, today | completed | "Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/ea024370301ex99-1_estrella.htm)) |
| July 14, 2025 | [Tab-cel (tabelecleucel) NDA/BLA submission](https://sec-api.dev/pdufa/tabelecleucel) | ATRA | cancer and autoimmune diseases, today | completed | "THOUSAND OAKS, Calif.(BUSINESS WIRE) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO or tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996dex991.htm)) |

## Drugs

- [ARTEMIS (artemis)](https://sec-api.dev/pdufa/artemis) (ESLA)
- [Tab-cel (tabelecleucel)](https://sec-api.dev/pdufa/tabelecleucel) (ATRA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/cancer-and-autoimmune-diseases-today.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "cancer and autoimmune diseases, today FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/cancer-and-autoimmune-diseases-today

```bibtex
@misc{secapidev_indications_cancer_and_autoimmune_diseases_today_20261116,
  title        = {cancer and autoimmune diseases, today FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/cancer-and-autoimmune-diseases-today}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_cancer_and_autoimmune_diseases_today_20261116","title":"cancer and autoimmune diseases, today FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/cancer-and-autoimmune-diseases-today","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
